Evofem Biosciences, Inc.
EVFM · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.00 | 0.01 |
| FCF Yield | -408.30% | -2,904.38% | -1,897.89% | -303.94% |
| EV / EBITDA | -6.67 | -2.68 | -0.88 | -0.95 |
| Quality | ||||
| ROIC | 71.75% | 96.21% | 12,525.64% | -1,035.67% |
| Gross Margin | 80.20% | 64.26% | 73.78% | 50.81% |
| Cash Conversion Ratio | 0.44 | -0.17 | 0.92 | 0.71 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.77% | 30.25% | 235.46% | – |
| Free Cash Flow Growth | 56.54% | 87.32% | 52.71% | -38.34% |
| Safety | ||||
| Net Debt / EBITDA | -6.54 | -2.66 | -0.83 | -0.65 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 2.43 | 3.84 | 0.82 | 0.53 |
| Cash Conversion Cycle | -1,204.12 | -743.90 | -769.66 | 47.71 |